Quick Answer
Protagenic Therapeutics, Inc.new reported Stockholders Equity of $1.01 million for fiscal year 2024.
Protagenic Therapeutics, Inc.new Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $1.01M | -72.4% |
| 2023 | $3.67M | -47.0% |
| 2022 | $6.92M | -30.4% |
| 2021 | $9.94M | +964.7% |
| 2020 | -$1.15M | -81.2% |
| 2019 | -$634.4K | -200.8% |
| 2018 | -$210.9K | -117.3% |
| 2017 | $1.22M | -50.8% |
| 2016 | $2.48M | +471.3% |
| 2015 | -$667.2K | -34.2% |
| 2015 | -$497.0K | -2266.7% |
| 2014 | -$21.0K | +82.6% |
| 2013 | -$120.6K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$2.39M | +27.9% | +49.1% |
| September 30, 2025 | -$4.70M | -90.3% | -18.3% |
| June 30, 2025 | -$3.97M | -126.7% | +19.8% |
| March 31, 2025 | -$4.95M | -176.8% | -49.3% |
| December 31, 2024 | -$3.32M | -190.5% | -34.3% |
| September 30, 2024 | -$2.47M | -159.5% | -40.9% |
| June 30, 2024 | -$1.75M | -132.4% | +2.0% |
| March 31, 2024 | -$1.79M | -127.9% | -148.8% |
- Protagenic Therapeutics, Inc.new showed a decrease of -72.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2024 period, Protagenic Therapeutics, Inc.new’s stockholders equity has grown by 940.2% (from -$120.6 thousand to $1.01 million).
- The most recent figure is from Protagenic Therapeutics, Inc.new’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: